Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is there any magic parameter to fetch the RSS feed for a message board WITHOUT the board description/infobox in the returned content? Some of the board descriptions are HUGE and it's a big waste of bandwidth for both IHUB and users. Please consider adding such a function if there's not a way to do it.
Thanks
Is there any magic parameter to fetch the RSS feed for a message board WITHOUT the board description in the returned content? Some of the board descriptions are HUGE and it's a big waste of bandwidth.
I managed to get a hold of IR and she said they'll definitely be issuing a PR as it's an important milestone for them. So hopefully we'll know all the details next week.
I'm not sure as the FedBizOps award notification isn't specific. I tried calling PIP IR, but she's out until Monday. Hopefully they will issue a PR to clarify as it looks like a nice sized award.
PIP gets $13m contract from HHS. Doesn't PIP use one of GTCBs patents?
http://www.fbo.gov/spg/HHS/NIH/NIAID/Awards/HHSN272200700033C.html
PIP $13m contract from HHS. I wonder if its for Protexia?
http://www.fbo.gov/spg/HHS/NIH/NIAID/Awards/HHSN272200700033C.html
Document Type: Award Notice
Solicitation Number: BAA--NIH-NIAID-DMID-07-37
Posted Date: Sep 21, 2007
Original Archive Date:
Current Archive Date:
Classification Code: A -- Research & Development
Set Aside: N/A
Naics Code: 541710 -- Research and Development in the Physical, Engineering, and Life Sciences
Contracting Office Address
Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions 6700 B Rockledge Room 3214 MSC7612, Bethesda, MD, 20892-7612, UNITED STATES
Description
Contract Award Date: Sep 21, 2007
Contract Award Number: HHSN272200700033C
Contract Award Amount: $13,920,347
Contract Line Item Number: NA
Contractor: PharmAthene, Inc. 175 Admiral Cochrane Drive Suite 101 Annaplois, MD 21401-7378
FWIW, I've been trying to get a hold of IR for the past week with no luck on callbacks. I decided to call back and ask the receptionist if she knew of any delays or if we could still expect something in May and she replied it should be out in a few days. IR was out of the office today at an outside meeting. I have no idea if she really knows, but hopefully we will get something in the next few days as she suggested.
6am Pacific Standard Time.
FWIW, I called CLSC last week and they said they hadn't received anything and were still on track for an April release as far as they know. I also asked when they usually do PRs and he said most likely premarket around 6am. So hopefully we'll wake up to some good news within the next week or two.
Good luck.
Make that Friday, 8/20
16:49 *DJ Google Says IPO Auction Will Open Friday 8/16
T warning. eom
1.5m SIRI block @ 3.27 AH
in some TRAD. Great popper numbers. eom
17:23 *DJ US Global Investors 3Q Net 3c/Shr Vs Loss 1c >GROW
FYI, GV earnings will be out sometime between today and Monday. Hopefully we'll see more good numbers. Their shareholder meeting is in a few weeks.
Ignore TBUS earnings post, goofy company keeps putting out PRs on their already announced earnings.
18:25 *DJ Digital Recorders 1Q Net 2c/Shr Vs Loss 6c>TBUS
Elan Licenses Its NanoCrystal Technology to Roche
Business Wire - April 21, 2004 01:30
Proprietary Elan technology helps improve drug delivery by transforming drugs into more effective and "user friendly" dosage forms to increase patient convenience and compliance.
ATHLONE, Ireland, Apr 21, 2004 (BUSINESS WIRE) -- Elan Pharma International Ltd., a subsidiary of Elan Corporation plc, today announced an agreement to license its proprietary NanoCrystal(TM) technology to Roche. NanoCrystal technology can improve the bioavailability of drugs by transforming them into nanometer-sized particles that can be used to create more effective and convenient dosage forms such as tablets, capsules, liquids, and powders. The license agreement will provide Roche with access to NanoCrystal technology and the rights to apply the technology to a drug candidate currently in clinical development.
"We are pleased that we are going to continue to work with Roche to apply our NanoCrystal technology to the formulation of this drug candidate," said Paul Breen, executive vice president, Global Services & Operations, Elan. "For more than 30 years, Elan has been working to meet the challenges of drug delivery and enhance the performance of drugs. By addressing poor water solubility through the use of NanoCrystal technology, Elan Pharma International Ltd. continues to play a role in furthering the development of drug candidates. In addition, our technology can help companies to differentiate their current therapies from the competition by creating more effective and convenient treatment options for patients."
In the agreement, Elan will provide Roche with formulation services and technology in exchange for research revenues, development milestones and royalties on sales of the product incorporating or made using NanoCrystal technology.
"We are pleased to bring our 2003 evaluation agreement with Elan to this next level and are enthusiastic about the potential of NanoCrystal technology," said Urs Saner, Roche's Head of Pharma Technical Development. "This agreement further strengthens our ability to deliver value for patients as we continue to develop innovative, differentiated medicines."
About Elan's NanoCrystal Technology
NanoCrystal technology may enhance the clinical performance of poorly water-soluble drugs by transforming them into nanometer-sized particles. An increasing number of the drug candidates synthesized each year by pharmaceutical companies are poorly water-soluble. Many of these potentially innovative drug candidates are often abandoned because of poor pharmacokinetic properties including absorption, distribution, metabolism, and excretion. NanoCrystal technology has the potential to rescue a significant percentage of these chemical compounds. The drug in nano-form can be incorporated into common dosage forms, including tablets, capsules, inhalation devices, sterile forms for injection, with the potential for substantial improvements to clinical performance. There are currently two pharmaceutical products that have been commercialised incorporating NanoCrystal technology, with several additional product launches anticipated over the next two years. The NanoCrystal technology is protected by 85 issued U.S. patents and 48 pending patents. More information about Elan's NanoCrystal technology is available at www.nanocrystal.com.
About Elan
Elan Pharma International Ltd. is an indirect wholly-owned subsidiary of Elan Corporation, plc, which is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock Exchanges.
SOURCE: Elan Pharma International Ltd.
Elan Corporation
Investors:
Emer Reynolds, +353-1-709-4000
800-252-3526
or
Media:
Anita Kawatra, 212-407-5755
800-252-3526
Here comes NYSE walkdown on ELN again...
ELN blocks near hod. eom
Lots of eod blocks in ELN
Cover block? 95k LOOK @ 1.70 AH
Here's a link that gives news headlines of companies in the soy field.
http://www.thesoydailyclub.com/Financial/news.asp
SIRI smoking AH. 4.20s eom
16:52 +DJ Elan Corp Cuts Targeted Genetics Stake To 14.8% Vs 17.7%
Played OTIV popper yesterday, out avg +0.48 eom
Look like NYSe ELN walkdown again today, sigh.
Elan Cuts 2004 Rev View To $475M-$525M
ELN down AH: Eisai to Purchase Elan's Interests in Zonegran in North America and Europe
NYSe trying hard to squash ELN into the close. Nice close over $20! Lets hope we get a nice gap up tomorrow.
ELN 317k & 311k blocks @ ask. eom
ELN back over 20. eom
All the more ELN ammo on the next pop over 20.
E*Trade To Replace FleetBoston In S&P 500 March 31
Does anybody know when CALM earnings are? Last report was on December 19th, so they should be due anytime, but I can't find any official date.
No email here either tonight, but it is on the website, so go take a peek there.
New Island Rule on subpenny orders.
In case you haven't heard, as of this past Monday, Island has new rules regarding placing subpenny orders. You can now only place subpenny orders (ie: 15.501) on Island for stocks under $1 and QQQ. All Island orders for stocks over $1 will automatically be rounded up/down to the nearest penny. Major bummer!
http://www.island.com/prodserv/developers/resources/emailarchive/20040303.asp
14:42 +DJ France Raises Terrorism Alert
ICGE Briefing: 14:55 ET ICGE finds late buy interest, lifting 18% on strong volume 0.42 +0.06: